The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| NRIX | -58.35% | -62.46% | -17.8% | -44% |
| S&P | +14.5% | +93.32% | +14.09% | +108% |
Nurix Therapeutics, Inc. is a biopharmaceutical company. It focuses on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $7.89M | -37.3% |
| Gross Profit | $2.89M | -65.7% |
| Gross Margin | 36.66% | -30.4% |
| Market Cap | $714.04M | -56.0% |
| Market Cap / Employee | $2.50M | 0.0% |
| Employees | 286 | 0.7% |
| Net Income | -$86.42M | -76.5% |
| EBITDA | -$86.39M | -71.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $78.44M | -20.8% |
| Accounts Receivable | $19.00M | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $52.70M | 155.9% |
| Short Term Debt | $3.79M | -42.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -47.25% | -4.2% |
| Return On Invested Capital | -41.23% | -52.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$60.10M | -35.0% |
| Operating Free Cash Flow | -$57.39M | -36.1% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.94 | 2.22 | 1.69 | 1.59 | -63.55% |
| Price to Sales | 31.78 | 22.88 | 10.09 | 9.39 | -71.10% |
| Price to Tangible Book Value | 3.94 | 2.22 | 1.69 | 1.59 | -63.55% |
| Enterprise Value to EBITDA | -19.09 | -13.07 | -10.59 | -4.79 | -82.90% |
| Return on Equity | -53.2% | -64.2% | -50.7% | -65.4% | 12.75% |
| Total Debt | $28.30M | $26.62M | $51.93M | $56.49M | 108.11% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
